Merkel cell polyomavirus and cutaneous Merkel cell carcinoma

“Further studies are required to fully resolve the prognostic significance of MCPyV in future Merkel cell carcinoma staging systems as well as its clinical and therapeutic implications.”

First draft submitted: 8 September 2016; Accepted for publication: 10 October 2016; Published online: 16 November 2016

Keywords: circulating biomarkers • immunotherapy • Merkel cell carcinoma • Merkel cell polyomavirus • sentinel node biopsy

Merkel cell carcinoma (MCC) is a rare aggressive neuroendocrine skin cancer of elderly patients. Generally, it originates from Merkel cells of the basal layer of the epidermis characterized by typical neuroendocrine granules (neuron-specific enolase; NSE+) and keratin filament (cytokeratin-20; CK20+). Its incidence has been increasing in the last two decades, likely because of improved ability to diagnose it. However, its mortality is still too high owing to systemic metastases (20–30% of MCC) despite the early detection of locally advanced disease through sentinel node (SN) biopsy and standard therapies [1].

Common risk factors for developing MCC include advanced age and immunocompromised state (secondary neoplasm, organ transplantation, HIV infection, drug-induced state and so on) and chronic UV exposure.

Histopathologically, the most important prognostic indicators are represented by size, thickness, depth, mitotic rate, lymphovascular invasion and tumor infiltrating CD8+ T cells (tumoral infiltration of lymphocytes [TIL]) of the primary MCC as well as SN status.

More recently, a human polyomavirus (MCPyV) has been discovered as an oncogenic agent of MCC [2]. It is a small, circular double-stranded DNA virus of the family Polyomaviridae. MCPyV sequences have revealed a very low genetic variability with the presence of five major variants corresponding to the different continents [3]. However, MCC is frequently reported in patients of Caucasian origin, mainly North America and Europe including Italy, while rarely in Asia and exceptionally in Africa.

To date, there is a robust collection of scientific evidence supporting its classification as a causative agent of MCC according to the WHO’s International Agency for Research on Cancer; however, a combination of this potential oncogenic pathway with other clinical factors and particularly immunosuppression seems to be mandatory for the pathogenesis of this rare skin cancer. In fact, MCPyV infection is common in the human population and skin is the most frequent asymptomatic location. Moreover, up to 80% of the adult population contains serum antibodies to the major capsid protein, VP1. However, the clonal integration of its viral genome into Merkel cells, and most frequently on chromosome 5, can induce mutations of the early region that result in truncation of the large T antigen (LTAg) inactivating pRB tumor suppressor function, while the small T antigen (STAg) coding sequence remains generally intact but promotes translation, instead. These MCC tumor-specific mutations abrogate viral DNA replication capacity and subsequently cell death, but preserve its oncogenic function with induction of uncontrolled cellular proliferation [4].

MCPyV LTAg and DNA have been detected by immunohistochemistry and PCR.
respectively, on formalin-fixed paraffin-embedded tissue samples in 80–100% of MCC; on the contrary, there are conflicting results on the rates of MCPyV in tumoral (non-MCC) and normal skin or other cancers [5–8].

Recent studies have supported the model that MCPyV contributes to the pathogenesis of most MCC; however, in reality, different oncologic pathways may be responsible for the development of MCPyV-negative MCC. In fact, while MCC incidence is very low, seroprevalence for the virus is high, which would suggest that infection by the virus is very common. Thus, the virus might be considered restrained whereas, as a matter of fact, it persists in an asymptomatic state that can only occasionally be disrupted to lead to neoplastic progression towards MCC. In addition, there are other factors that can induce genetic mutations such as TP53, PIK3CA and so on in MCPyV-negative MCC [9,10].

“...anti-PD-L1 or anti-PD-1 immunotherapies, preferably in combination with molecular targeted treatment, might become the gold standard for metastatic disease, independent of the presence of the virus.”

Moreover, MCPyV-positive MCCs are generally characterized by standard differentiation (CK20+) and high immunological response (TIL and peripheral blood specific CD8+ lymphocytes as well as serum anti-MCPyV antibodies titer) with favorable prognosis. In fact, high TIL and particularly CD8+ seems to greatly influence the population of MCC cells killing tumoral cells through cytotoxic mechanisms with better survival [11]. Besides, high titers of MCPyV antibodies and particularly anti-LTAg, but above all circulating specific CD8+ cells, seem to be associated with better survival. On the contrary, different oncologic pathways seem to be responsible for the development of uncommon MCPyV-negative MCC [12,13], which are frequently characterized by divergent differentiation and low immunological response with poor prognosis [14].

The management of MCC remains challenging following this new knowledge into its molecular biology [15]; this is somewhat analogous to oropharyngeal cancer following the identification of human papillomavirus as a causative agent. Further studies are required to fully resolve the prognostic significance of MCPyV [16] in future MCC staging systems as well as its clinical and therapeutic implications. In fact, the correlation of MCPyV-positive/negative MCC with other common prognostic factors and particularly SN status might eventually clarify the independent prognostic value of MCPyV [6,17], confirming the different pathogenetic pathways of the two variants [9,18].

According to the EORTC-SPECTA and US-based NCI-MATCH programmes, clinical trials using novel targeted and immunotherapies are currently under investigation; circulating tumor cells might serve as biomarkers for disease surveillance in agreement with antitumoral activity (anti-MCPyV CD8+ T cells rather than antibodies) [19,20]. MCPyV-positive tumors as well as these infiltrating and circulating specific T cells seem to express respectively higher levels of PD-L1 and PD-1 [21,22] in comparison with MCPyV-negative ones. Therefore, anti-PD-L1 or anti-PD-1 immunotherapies, preferably in combination with molecular targeted treatment, might become the gold standard for metastatic disease, independent of the presence of the virus [23]. In fact, both radiation and chemotherapies have demonstrated poor results in the adjuvant setting in terms of regional control and survival benefit, respectively, with high toxicity in elderly patients, while adjuvant immunotherapy (anti-PD-1 or anti-PD-L1 rather than anti-CTLA-4) might be confirmed more efficacious with acceptable toxicity [23,24]. Alternative immunotherapy-based treatments (vaccines, interferon, interleukins and so on) are also being tested [25–27].

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Open access

This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

Papers of special note have been highlighted as:
• of interest; •• of considerable interest

1. Lebbe C, Becker JC, Grob JJ et al. Diagnosis and treatment of Merkel cell carcinoma. European consensus-based interdisciplinary guideline. Eur. J. Cancer 51(16), 2396–2403 (2015).

2. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319(5866), 1096–1100 (2008).

3. Martel-Jantin C, Filippone C, Cassar O et al. Genetic variability and integration of Merkel cell polyomavirus in...

4. EDF/EADO/EORTC guidelines on Merkel cell carcinoma (MCC).
Merkel cell carcinoma. *Virology* 426(2), 134–142 (2012).

- Shows the oncogenic mechanism of MCPyV in MCC.

4 Spurgeon ME, Lambart PF. Merkel cell polyomavirus: a newly discovered human virus with oncogenic potential. *Virology* 435, 118–130 (2013).

5 Schrama D, Becker JC. Merkel cell carcinoma – pathogenesis, clinical aspects and treatment. *J. Eur. Acad. Dermatol. Venereol.* 25, 1121–1129 (2011).

6 Sihto H, Kukko H, Kolonen V, Sankila R, Boehling T, Joensuu H. Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. *J. Natl Cancer Inst.* 101, 938–945 (2009).

7 Rodig SJ, Cheng J, Wardzala J et al. Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. *J. Clin. Invest.* 122(12), 4645–4653 (2012).

- Shows PCR as the best technique to detect MCPyV in MCC.

8 Pantulu ND, Pallasch CP, Kurz AK et al. Detection of a novel truncating Merkel cell polyomavirus large T antigen deletion in chronic lymphocytic leukemia cells. *Blood* 116(24), 5280–5284 (2010).

9 Harms PW, Patel RM, Verhaegen ME et al. Distinct gene expression profiles of viral- and nonviral-associated Merkel cell carcinoma revealed by transcriptome analysis. *J. Invest. Derm.* 133, 936–945 (2013).

10 Eristad DJ, Cusack JC Jr. Mutational analysis of Merkel cell carcinoma. *Cancers* 6(4), 2116–2136 (2014).

11 Paulson KG, Iyer JG, Tegeder AR et al. Transcriptome-wide studies of Merkel cell carcinoma and validation of intratumoral CD8⁺ lymphocyte invasion as an independent predictor of survival. *J. Clin. Oncol.* 20(12), 1539–1546 (2011).

12 Miner AG, Patel RM, Wilson DA et al. Cytokeratin 20-negative Merkel cell carcinoma is infrequently associated with the Merkel cell polyomavirus. *Mod. Pathol.* 28, 498–505 (2015).

13 Martin B, Poblet E, Rios JJ et al. Merkel cell carcinoma with divergent differentiation: histopathological and immunohistochemical study of 15 cases with PCR analysis for Merkel cell polyomavirus. *Histopathology* 62(5), 711–722 (2013).

14 Higaki-Mori H, Kuwamoto S, Iwasaki T et al. Association of Merkel cell polyomavirus infection with clinicopathological differences in Merkel cell carcinoma. *Hum. Pathol.* 43(12), 2282–2291 (2012).

15 Tothill R, Estall V, Rischin D. Merkel cell carcinoma: emerging biology, current approaches and future directions. *Am. Soc. Clin. Oncol. Educ. Book* 2015, e519–e526 (2015).

- American Society of Clinical Oncology guidelines on MCC.

16 Peitsch WK. Associations between Merkel cell carcinoma and Merkel cell polyomavirus. *Br. J. Dermatol.* 173(1), 7–8 (2015).

17 Loyo M, Schussel J, Colantuoni E et al. Detection of Merkel cell virus and correlation with histologic presence of Merkel cell carcinoma in sentinel lymph nodes. *Br. J. Cancer* 106(7), 1314–1319 (2012).

18 Amber K, McLeod MP, Nouri K. The Merkel cell polyomavirus and its involvement in Merkel cell carcinoma. *Dermatol. Surg.* 39, 232–238 (2013).

19 Gaiser MR, Daily K, Hoffmann J, Brune M, Enk A, Brownell I. Evaluating blood levels of neuron specific enolase, chromogranin A, and circulating tumor cells as Merkel cell carcinoma biomarkers. *Oncotarget* 6(28), 26472–26482 (2015).

20 Blom A, Bhatia S, Pietromonaco S et al. Clinical utility of a circulating tumor cell assay in Merkel cell carcinoma. *J. Am. Acad. Dermatol.* 70(3), 449–455 (2014).

21 Lipson EJ, Vincent JG, Loyo M et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. *Cancer Immunol. Res.* 1, 54–63 (2013).

22 Afanasiev OK, Yelistratova L, Miller N et al. Merkel polyomavirus-specific T cells fluctuate with Merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. *Clin. Cancer Res.* 19, 5351–5360 (2013).

23 Nghiem PT, Bhatia S, Lipson EJ et al. PD-1 blockade with pembrolizumab in advanced Merkel cell carcinoma. *N. Engl. J. Med.* 374(26), 2542–2552 (2016).

- Shows the preliminary results of a new therapeutic approach for MCC.

24 Sanlorenzo M, Vujic I, Daud A et al. Pembrolizumab cutaneous adverse events and their association with disease progression. *JAMA Dermatol.* 151(11), 1206–1212 (2015).

25 Rabinowits G. Systemic therapy for Merkel cell carcinoma: what’s on the horizon? *Cancers* 6, 1180–1194 (2014).

26 Vandeven N, Nghiem P. Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. *Immunotherapy* 8(8), 907–921 (2016).

27 Cassler NM, Merrill D, Bichakjian CK, Brownell I. Merkel cell carcinoma therapeutic update. *Curr. Treat. Options Oncol.* 17(7), 36 (2016).

- An excellent overview of the new therapeutic strategies for MCC.